Human immune response to immunotoxins
The potential value of immunotoxins (ITs) in the treatment of human cancer may eventually prove to be limited by the development of host antibodies against the conjugate. The development of antimurine antibodies after administration of unconjugated monoclonal antibodies is well documented and has been associated with more rapid murine antibody clearance and decreased clinical effect [1, 2]. Similarly, antitoxin antibodies have been detected in both animals and humans treated with ricin and abrin [3, 4]. When given lethal doses of ricin, survival was prolonged in mice which had developed antiricin antibody levels in excess of 10–20 ng/ml .
KeywordsToxicity Albumin Attenuation Leukemia Polyethylene
Unable to display preview. Download preview PDF.
- 1.Sawler, D.L., Bartholomew, R.M., Smith, L.M., and Dillman, R.O. (1985) Human immune response to multiple injections of murine monoclonal IgG. J. Immunol., 135, 1530–1535.Google Scholar
- 6.Ramakrishnan, S., and Houston, L.L. (1982) Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibiters: Pokeweed antiviral protein or ricin A chain. Cancer Res., 44, 1398–1404.Google Scholar
- 7.Hertler, A.A., Schlossman, D.M., Lester, C., Balis, F., Thorpe, P., Poplack, D., and Frankel, A. (1987) Intrathecal administration of WT1-ricin A chain immunotoxin. Proc. of ASCO, 5, 989, pg 251.Google Scholar
- 8.Spitler, L.E., del Rio, M., Khentigan, A., Wedel, N.I., Brophy, N.A., Miller, L.L., Harkonen, W.S., Rosendorf, L.L., Lee, H.M., Mischak, R.P., Kawahata, R.T., Stoudemire, J.B., Fradkin, L.B., Bautista, E.F., and Scannon, P.J. (1987) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin Cancer Res., 47, 1717–1723.PubMedGoogle Scholar
- 10.Hertler, A.A., Schlossman, D.M., Borowitz, M.J., Laurent, G., Jansen, F.K., Schmidt, C., and Frankel, A.E. A phase I study of T101-ricin A-chain immunotoxin in refractory chronic lymphocytic leukemia, submitted for publication.Google Scholar
- 12.Jaffers, G.J., Colvin, R.B., Cosimi, A.B., Giorgi, J.V., Goldstein, G., Fuller, T.C., Kurnick, J.T., Lillehei, C., and Russell, P.S. (1983) The human immune response to murine OKT3 monoclonal antibody. Transplant Proc., 15, 646–648.Google Scholar
- 13.Abuchowski, A., van Es, T., Palczuk, N.C., and Davis, F.F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biochem., 252, 3578–3581.Google Scholar
- 16.Hershfield, M.S., Buckley, R.H., Greenberg, M.L., Melton, A.L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M.L., Kobayashi, R.H., Kobayashi, A.L., and Abuchowski, A. (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med., 316, 589–596.PubMedCrossRefGoogle Scholar